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Breed Distribution of SOD1 Alleles Previously Associated with
Canine Degenerative Myelopathy
R. Zeng, J.R. Coates, G.C. Johnson, L. Hansen, T. Awano, A. Kolicheski, E. Ivansson, M. Perloski,
K. Lindblad-Toh, D.P. O’Brien, J. Guo, M.L. Katz, and G.S. Johnson
Background: Previous reports associated 2 mutant SOD1 alleles (SOD1:c.118A and SOD1:c.52T) with degenerative
myelopathy in 6 canine breeds. The distribution of these alleles in other breeds has not been reported.
Objective: To describe the distribution of SOD1:c.118A and SOD1:c.52T in 222 breeds.
Animals: DNA from 33,747 dogs was genotyped at SOD1:c.118, SOD1:c.52, or both. Spinal cord sections from 249 of
these dogs were examined.
Methods: Retrospective analysis of 35,359 previously determined genotypes at SOD1:c.118G>A or SOD1:c.52A>T
and prospective survey to update the clinical status of a subset of dogs from which samples were obtained with a relatively
low ascertainment bias.
Results: The SOD1:c.118A allele was found in cross-bred dogs and in 124 different canine breeds whereas the SOD1:
c.52T allele was only found in Bernese Mountain Dogs. Most of the dogs with histopathologically confirmed degenerative
myelopathy were SOD1:c.118A homozygotes, but 8 dogs with histopathologically confirmed degenerative myelopathy were
SOD1:c.118A/G heterozygotes and had no other sequence variants in their SOD1 amino acid coding regions. The updated
clinical conditions of dogs from which samples were obtained with a relatively low ascertainment bias suggest that SOD1:
c.118A homozygotes are at a much higher risk of developing degenerative myelopathy than are SOD1:c.118A/G heterozyg-
otes.
Conclusions and Clinical Importance: We conclude that the SOD1:c.118A allele is widespread and common among pri-
vately owned dogs whereas the SOD1:c.52T allele is rare and appears to be limited to Bernese Mountain Dogs. We also
conclude that breeding to avoid the production of SOD1:c.118A homozygotes is a rational strategy.
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Taken literally, the term “canine degenerative mye-lopathy” (DM) could refer to a wide variety neu-
rologic diseases of dogs. Since 1973, however, the term
DM most often has been used to describe a progres-
sive neurodegenerative disease (or diseases) with char-
acteristic clinical signs and distinct histopathologic
spinal cord lesions.1–13 Most dogs are at least 8 years
old before the onset of clinical signs. The initial signs
of DM typically include asymmetric general proprio-
ceptive ataxia and spastic paresis in the pelvic limbs.
At this stage, segmental spinal reflexes are indicative
of upper motor neuron loss. Disease progression is
relentless, and dog owners often elect euthanasia
within 1 year after onset of clinical signs when their
dogs become paraplegic.2 When euthanasia is delayed,
weakness can ascend to the thoracic limbs with the
emergence of lower motor neuron signs such as flaccid
tetraplegia, widespread muscle atrophy, dysphagia,
and inability to bark.3–5 Because a variety of common
acquired compressive spinal cord diseases can mimic
the early signs of DM by compromising upper motor
neuron pathways, a definitive diagnosis of DM can
only be made postmortem by the histopathologic
observation of axonal and myelin degeneration along
with astrogliosis in spinal cord funiculi. These degener-
ative changes can occur throughout the spinal cord
white matter, but usually are most severe in the dorsal
portion of the lateral funiculus in the middle to lower
thoracic spinal cord segments.1,6–9 Other histopatho-
logic lesions in dogs with DM can include denervation
atrophy in muscle and nerve fiber loss with axonal
degeneration and secondary demyelination.3,10
In 2009, we reported that dogs with histopathologi-
cally confirmed DM were homozygous for the A allele
of a SOD1 missense mutation, SOD1:c.118G>A,
which predicts a p.E40K amino acid substitution in
superoxide dismutase 1 (SOD1).3 More recently, we
described a histopathologically confirmed case of DM
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in a dog that tested homozygous for the ancestral
SOD1:c.118G allele.11 This dog was homozygous for
the T allele of a different SOD1 missense mutation,
c.52A>T, which predicts a p.S18T amino acid substi-
tution. The SOD1:c.52T homozygote was a Bernese
Mountain Dog. The earlier study that identified the
SOD1:c.118G>A mutation focused on 5 canine
breeds: Boxer, Chesapeake Bay Retriever, German
Shepherd Dog, Pembroke Welsh Corgi, and Rhodesian
Ridgeback.3 Nonetheless, members of many other
canine breeds have been diagnosed with DM.2,5,12,13
To provide a broader view of the potential contribu-
tion of the known SOD1 missense mutations across
multiple canine breeds, we here report 35,359 geno-
types at SOD1:c.118, SOD1:c.52, or both determined
using DNA samples from members of 222 canine
breeds, including 249 dogs from which spinal cord seg-
ments were obtained post mortem for histopathologic
evaluation.
Materials and Methods
This report includes the results of all SOD1:c.118G>A or
SOD1:c.52A>T genotype determinations completed at the Uni-
versity of Missouri before April 5, 2013. These genotypes were
generated by testing DNA from a variety of sources, including
previously collected samples in the University of Missouri
Animal DNA Repository or in the Canine Health Information
Center DNA Bank (offa.org/chicdnabank.html). Other samples
were submitted by dog owners or their veterinarians to the Uni-
versity of Missouri or to the Orthopedic Foundation for Animals
for DNA testing for mutations associated with a variety of inher-
ited disorders including DM, mostly for diagnostic purposes or
to be used for marker-assisted mate selection. DNA was
extracted from EDTA-anticoagulated blood samples as previ-
ously described.3 Other samples were collected using buccal
swabsa and stored on DNA storage cards.a DNA was extracted
from 3.2 mm diameter disks punched from the cards into 96-well
plates with an electric puncher.b After 5 washes with distilled
water at room temperature, 40 lL of distilled water was added
to each well that contained a disk and the 96-well plates were
heated at 95°C for 30 minutes. The dissolved DNA samples were
separated from the disks by transfer to another 96-well plate.
Genotypes at SOD1:c.118G>A were determined as previously
described3 or with a TaqMan allelic discrimination assay,14 which
used 5′-GTGGGCCTGTTGTGGTATCA-3′ with 5′-CAAACTGA
TGGACGTGGAATCC-3′ for the PCR primers and 5′-VIC-CTCG
CCTTTAGTCAGC-MGB-3′ (A allele) and 5′-FAM-CGCCTT
CAGTCAGC-MCB-3′ (G allele) for the competing probes. Geno-
types at SOD1:c.52A>T also were determined with a TaqMan
allelic discrimination assay. The PCR primer sequences were 5′-G
CCGTGTGCGTGTTGAAG-3′ with 5′-CCCGCCCTTGCCTTC
T-3′ and the probe sequences were 5′-VIC-AGTGGATGGTGC
CCTC-MGB-3′ for the A allele and 5′-FAM-TGGATGGAG
CCCTC-MGB-3′ for the T allele.
The resequencing of SOD1 in DNA from individual dogs was
accomplished by PCR amplification with primers flanking the
coding regions and exon-intron junctions of all 5 SOD1 exons.
Table S1 contains the PCR primer sequences, the expected sizes
of the amplicons, and the annealing temperatures used for these
PCR amplifications. The PCR amplifications for exon 2 through
exon 5 were done with a kitc and 40 cycles of 95°C for 30 sec-
onds, the annealing temperature for 30 seconds, followed by an
additional 30 seconds at 72°C. For exon 1, the PCR amplifica-
tions were done with a different kitd designed for use with G-C
rich templates and 24 cycles of 95°C for 30 seconds, 64°C for
30 seconds, followed by an additional 30 seconds at 72°C. The
PCR amplicons were purified with a spin columne and sequenced
in both directions with an automated Sanger sequencer.f DNA
sequence analysis softwareg was used to compare the nucleotide
sequences from individual dogs to one another and to build 3.1
of the NCBI canine genome reference sequence.
All of the 249 canine thoracic spinal cords in this study were
dissected at necropsy from dogs that were at least 8 years old.
They were fixed and embedded in paraffin. Sections of the
paraffin-embedded samples were stained with hematoxylin and
eosin and with either luxol fast blue-periodic acid Schiff or luxol
fast blue-cresyl violet to detect neuronal fiber and myelin loss as
previously described.3 Previously described procedures3 were used
to immunostain spinal cord sections for glial fibrillary acid pro-
tein to detect astrogliosis and for SOD1 to detect SOD1-contain-
ing cytoplasmic aggregates. The diagnosis of DM was confirmed
by demonstration of the characteristic pattern of axonal degener-
ation, myelin loss, and gliosis in the thoracic spinal cord. All
spinal cord sections were examined by the same board-certified
veterinary pathologist (GCJ).
Results
Before April 5, 2013, DNA from 33,746 individual
dogs had been genotyped for the DM-associated
SOD1:c.118G>A mutation at the University of
Missouri. This included 1,368 mixed-breed dogs and
32,378 dogs claimed by their owners to be purebred
representatives of 222 different canine breeds. Almost
half (49%) of these dogs (n = 16,550) were homozy-
gous for the ancestral (or G) allele whereas 9,112 dogs
(27%) were A/G heterozygotes and 8,084 dogs (24%)
were homozygous for the mutant (or A) allele. The fre-
quency of the A allele for all genotyped dogs was
37%. Table S2 shows the uneven distributions of A
allele frequencies among all 222 of the genotyped
canine breeds. The A allele was detected in at least 1
representative from 124 breeds. Table 1 shows the dis-
tribution of A allele frequencies in the subset of breeds
with at least 50 genotyped representatives. Among the
65 breeds in this subset, the Wire Fox Terrier had the
highest SOD1:c.118A allele frequency (94%) whereas
for 9 of these breeds all representatives tested homozy-
gous for the c.118G allele.
A total of 1,613 dogs were genotyped for the SOD1:
c.52A>T mutation. All 701 tested mixed-breed dogs
and members of 56 breeds other than the Bernese
Mountain Dog were homozygous for the ancestral
c.52A allele (see Table S3). Among the 912 genotyped
Bernese Mountain Dogs, 59 were heterozygotes and 2
(including a previously described dog11) were homozy-
gous for the SOD1:c.52T allele. Thus, the SOD1:c.52T
allele frequency among the 912 genotyped Bernese
Mountain Dogs was 3.5%. All but 1 of these Bernese
Mountain Dogs also were genotyped at SOD1:c.118.
Table 2 shows the distribution of genotypes among the
911 Bernese Mountain Dogs genotyped at both SOD1
loci. Notable was the absence of dogs with any of the
3 genotypes (c.52T/T and c.118A/A; c.52T/T and
c.118G/A; and, c.52A/T and c.118A/A) that require the
presence of a haplotype consisting of both c.52T and
c.118A. Because the SOD1:c.52T and SOD1:c.118A
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alleles rarely, if ever, occur together as a haplotype,
the 24 dogs that are heterozygous at both c.52 and
c.118 are most likely compound heterozygotes. Eleven
of the 24 compound heterozygous Bernese Mountain
Dogs were >8 years old in May 2013 and we were able
to ascertain the clinical status of 6 of them. One of
them died from unrelated causes at 9.0 years of age.
Another 1 was unaffected at 8.3 years of age. The
other 4 compound heterozygous Bernese Mountain
Dogs have exhibited clinical signs of DM, including 1
that was euthanized because of advanced disease. The
histopathologic findings for this dog confirmed the
diagnosis of DM.
Conclusions from histopathologic examination of
249 spinal cords from mixed-breed dogs and purebred
dogs from 38 different breeds, including 213 dogs
which previously had received a presumptive diagnosis
of DM, are summarized in Table S4. In this table (and











FrequencyG/G G/A A/A G/G G/A A/A
Wire Fox Terrier 79 1 7 71 0.94 Borzoi 787 548 209 30 0.17
Pembroke
Welsh Corgi
3,209 220 898 2,091 0.79 English Springer
Spaniel
127 97 17 13 0.17
Boxer 3,934 500 1,177 2,257 0.72 Border Collie 80 63 7 10 0.17
Cavalier King
Charles Spaniel
73 10 27 36 0.68 French Bulldog 87 64 18 5 0.16
Pit Bull Terrier 53 23 6 24 0.51 Irish Setter 57 42 12 3 0.16
American
Water Spaniel
91 22 46 23 0.51 Shiloh Shepherd 221 161 53 7 0.15
Australian Shepherd 113 57 20 36 0.41 Great Pyrenees 85 68 10 7 0.14
Collie 151 73 39 39 0.39 Saint Bernard 78 60 15 3 0.13
Soft Coated
Wheaten Terrier
88 45 18 25 0.39 Chinese Crested 53 40 13 0 0.12
Hovawart 64 31 17 16 0.38 Staffordshire
Bull Terrier
52 46 1 5 0.11
Bernese
Mountain Dog
2,413 941 1,112 360 0.38 Mastiff (English
Mastiff)
114 93 19 2 0.10
Chesapeake
Bay Retriever
2,344 958 1,034 352 0.37 Norwich Terrier 74 60 14 0 0.09
German
Shepherd Dog
6,458 3,155 1,884 1,419 0.37 Australian Cattle
Dog
61 53 5 3 0.09
Tibetan Terrier 69 32 24 13 0.36 Coton de Tulear 110 94 16 0 0.07
Kerry Blue Terrier 558 254 223 81 0.34 Labrador Retriever 475 433 19 23 0.07
Czechoslovakian
Wolfdog
52 24 21 7 0.34 Nova Scotia Duck
Tolling Ret.
59 52 6 1 0.07
Cardigan
Welsh Corgi
544 271 194 79 0.32 Poodle-Standard 533 468 60 5 0.07
Pug 382 202 113 67 0.32 Beagle 57 52 3 2 0.06
Jack Russell Terrier 60 36 10 14 0.32 Belgian Malinois 101 92 6 3 0.06
Bloodhound 264 125 117 22 0.30 Tenterfield Terrier 66 59 7 0 0.05
Canaan Dog 169 87 67 15 0.29 Siberian Husky 97 92 3 2 0.04
Rhodesian
Ridgeback
2,645 1,381 1,023 241 0.28 Dalmatian 180 172 4 4 0.03
Kuvasz 75 46 19 10 0.26 Golden Retriever 334 322 2 10 0.03
Welsh Terrier 72 41 25 6 0.26 Rottweiler 76 73 2 1 0.03
Komondor 55 32 22 1 0.22 Doberman Pinscher 55 54 0 1 0.02
Shetland Sheepdog 58 41 10 7 0.21 Alaskan Malamute 61 60 0 1 0.02
Tamaskan (Aatu
Tamaskan)
59 40 17 2 0.18 Newfoundland 62 61 0 1 0.02
Puli 123 87 29 7 0.17 Rat Terrier 63 62 1 0 0.01
Breed (and number tested) for 9 breeds represented only by G/G homozygotes: Weimaraner (112); Great Dane (84); Field Spaniel
(75); Basenji (59); Akita (58); English Cocker Spaniel (56); Greater Swiss Mountain Dog (53); Bouvier des Flandres (51); Dachshund
(50).
Table 2. Distribution of combined SOD1:c.52 and




A/A 316 399 136
A/T 35 24 0
T/T 2 0 0
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in Table 3), the 45 spinal cords from dogs for which a
presumptive diagnosis of DM was not supported by
the histopathologic findings were grouped with the 36
spinal cords from dogs euthanized for reasons unre-
lated to DM and classified as controls. Of the 168
spinal cords with a confirmed diagnosis of DM, 157
were from SOD1:118A homozygous dogs, 9 (2 Bernese
Mountain Dogs, 2 Chesapeake Bay Retrievers, 2
German Shepherd Dogs, 2 Rhodesian Ridgebacks, and
1 Alaskan Husky) were from SOD1:c.118A/G hetero-
zygotes, and 2 were from SOD1:c.118G homozygotes.
One of the 2 SOD1:118A/G heterozygous Bernese
Mountain Dogs was a c.118A/G plus c.52A/T com-
pound heterozygote as discussed above. The coding
regions in all 5 SOD1 exons from the other 8 SOD1:
c.118A/G heterozygotes with confirmed DM were ana-
lyzed by PCR amplification and automated Sanger
sequencing, but no additional missense mutations were
found. One of the 2 SOD1:118G homozygotes with
confirmed DM was a previously described Bernese
Mountain Dog that was homozygous for the T allele
at SOD1:c.5211 and other was from a 11-year-old
German Shepherd Dog with a slightly slower rate of
disease progression and a more pronounced sensorimo-
tor neuropathy than is typical for DM. No potentially
causal SOD1 sequence variants were found in DNA
from this dog.
One hundred and seventy-three spinal cords, includ-
ing 115 with confirmed DM and 58 controls, were
examined by immunohistochemistry with anti-SOD1
antibodies. The results are summarized in Table 3 and
photomicrographs from selected cases are shown in
Fig S1. Aggregates containing SOD1 antigen were
detected in all 105 spinal cords from SOD1:c.118A
homozygous dogs with confirmed DM. In addition,
the SOD1:c.52T homozygous Bernese Mountain Dog
and all 8 of the examined SOD1:c.118A/G heterozy-
gous dogs with histopathologically confirmed DM had
SOD1 aggregates whereas no SOD1 aggregates were
detected in the SOD1:c.118G homozygous German
Shepherd Dog with confirmed DM. Among the 58
control spinal cords examined by immunohistochemistry,
Table 3. Results of immunohistochemical staining for SOD1 aggregates.
Breed Number Tested
Confirmed DM Controls
G/G G/A A/A G/G G/A A/A
Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg
Alaskan Husky 1 0 0 1 0 0 0 0 0 0 0 0 0
American Eskimo Dog 1 0 0 0 0 1 0 0 0 0 0 0 0
American Staffordshire Terrier 1 0 0 0 0 0 0 0 0 0 0 1 0
Australian Shepherd 3 0 0 0 0 2 0 0 0 0 1 0 0
Beagle 2 0 0 0 0 0 0 0 2 0 0 0 0
Bernese Mountain Dog 19 1 0 2 0 13 0 0 0 1 0 0 2
Bloodhound 1 0 0 0 0 1 0 0 0 0 0 0 0
Borzoi 1 0 0 0 0 1 0 0 0 0 0 0 0
Boxer 35 0 0 0 0 24 0 0 1 1 5 2 2
Caanan Dog 1 0 0 0 0 0 0 0 0 0 1 0 0
Cardigan Welsh Corgi 1 0 0 0 0 1 0 0 0 0 0 0 0
Cavalier King Charles Spaniel 2 0 0 0 0 1 0 0 0 0 0 1 0
Chesapeake Bay Retriever 6 0 0 2 0 3 0 0 0 0 0 1 0
English Cocker Spaniel 4 0 0 0 0 0 0 0 4 0 0 0 0
English Springer Spaniel 3 0 0 0 0 3 0 0 0 0 0 0 0
German Shepherd Dog 16 0 1 2 0 7 0 0 2 1 2 0 1
Golden Retriever 1 0 0 0 0 1 0 0 0 0 0 0 0
Kerry Blue Terrier 2 0 0 0 0 2 0 0 0 0 0 0 0
mixed breed 6 0 0 0 0 5 0 0 0 0 0 0 1
Pembroke Welsh Corgi 40 0 0 0 0 27 0 0 1 1 6 1 4
Pug 3 0 0 0 0 2 0 0 0 0 0 0 1
Rhodesian Ridgeback 11 0 0 1 0 5 0 0 1 0 3 0 1
Rottweiler 1 0 0 0 0 0 0 0 1 0 0 0 0
Rough Collie 1 0 0 0 0 1 0 0 0 0 0 0 0
Scottish Deerhound 1 0 0 0 0 0 0 0 1 0 0 0 0
Soft Coated Wheaten Terrier 2 0 0 0 0 2 0 0 0 0 0 0 0
Standard Poodle 2 0 0 0 0 1 0 0 1 0 0 0 0
Standard Schnauzer 1 0 0 0 0 0 0 0 1 0 0 0 0
Tibetan Terrier 2 0 0 0 0 0 0 0 0 0 2 0 0
White German Shepherd 1 0 0 0 0 0 0 0 0 0 1 0 0
Wire Fox Terrier 2 0 0 0 0 2 0 0 0 0 0 0 0
Total 173 1 1 8 0 105 0 0 15 4 21 6 12
“Pos” means aggregates containing SOD1 antigen were detected; “Neg” means aggregates containing SOD1 antigen were not
detected.
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6 of 18 spinal cords from dogs that were homozygous
for the SOD1:c.118A allele had SOD1 aggregates and
4 of 25 spinal cords from dogs that were A/G hetero-
zygotes at SOD1:c.118 had SOD1 aggregates. These
aggregates were not detected in any of the 15 spinal
cords from control dogs that were homozygous for the
SOD1:c.118G allele.
The occurrence of histopathologically confirmed
DM in 8 dogs that were A/G heterozygotes at SOD1:
c.118 and had no other SOD1 sequence variants
prompted us to estimate the relative risks for develop-
ing DM for dogs with different SOD1:c.118 genotypes
(A/A versus A/G versus G/G). To avoid the large ascer-
tainment biases associated with most of the genotypes
in this report, we restricted our analysis to dogs that
were clinically normal and <8 years old when samples
were submitted for genotyping, but that were
>10 years old when an update of their clinical status
was requested from their owners in the form of an
online survey. Dog owners responded by providing
clinical updates for 137 dogs of 17 different breeds
(Table S5). As indicated in Table 4, 18 of the 30 dogs
with the homozygous SOD1:c.118A genotype devel-
oped clinical signs consistent with DM whereas only 2
of the 55 SOD1:c.118A/G heterozygous dogs and only
3 of the 52 SOD1:c.118G homozygous dogs developed
compatible clinical signs.
Discussion
The DM-associated SOD1:c.118A allele appears to
be widely distributed in the overall canine population.
The allele was present in representatives from 124 dif-
ferent breeds or varieties, which accounts for 56% of
the breeds represented in this study. For the 98 breeds
in which only the SOD1:c.118G allele was detected,
the mean number of genotyped dogs from each breed
was only 23.4. Furthermore, in 49 of these breeds, <10
dogs were genotyped. The genotyping of more breed
members would likely identify additional breeds har-
boring the SOD1:c.118A allele. The widespread distri-
bution of this mutation among breeds suggests that it
originated before the establishment of individual
breeds. Because of the late onset of the disease signs
associated with this mutation, there would be little nat-
ural selective pressure to decrease the frequency of the
mutant allele. The breed-specific SOD1:c.118A allele
frequencies varied greatly even among similar breeds.
For example, all 53 of the genotyped Greater Swiss
Mountain Dogs were homozygous for the ancestral
SOD1:c.118G allele whereas the SOD1:c.118A allele
frequency was 38% for the 2,413 genotyped represen-
tatives of the closely related Bernese Mountain Dog
breed. Furthermore, even though before 1985 Smooth
Fox Terriers and the Wire Fox Terriers were consid-
ered by the American Kennel Club to be varieties of a
single breed which could be interbred, the SOD1:
c.118A allele frequency was 94% for the 79 genotyped
Wire Fox Terriers whereas all 30 Smooth Fox Terriers
were SOD1:c.118G homozygotes. Because dogs were
selected for genotyping for a variety of reasons, the
breed-specific allele frequencies determined here are
unlikely to reflect the precise overall allele frequencies
for the various breeds.
In contrast to the widespread distribution of the
SOD1:c.118A allele, the SOD1:c.52T allele appears to
be restricted to Bernese Mountain Dogs. Even among
the 912 genotyped Bernese Mountain Dogs, the
SOD1:c.52T allele frequency was only 3.5%, much
lower than the 38% SOD1:c.118A allele frequency in
this breed. Of the 2 SOD1:c.52T homozygous Bernese
Mountain Dogs, 1 developed DM as previously
described11 and the other was normal at the time of
sample submission and is currently <8 years of age
and thus younger than the expected age of onset for
DM. The 24 Bernese Mountain Dogs that were het-
erozygous at both SOD1:c.52 and SOD1:c.118 were
most likely compound heterozygotes. The develop-
ment of signs of DM in 4 of these compound
heterozygotes supports our earlier assertion that the
SOD1:c.52T allele can cause or contribute to the
development of DM.11 We now know, however, that
some SOD1:c.118 heterozygous dogs with no other
SOD1 missense mutations have developed DM (see
below). Documented development of DM in addi-
tional SOD1:c.52T homozygotes would provide more
definitive evidence that the SOD1:c.52T allele can
cause DM.
Crisp et al15 have isolated detergent-insoluble
SOD1 aggregates from the spinal cords of dogs with
DM and shown that the amount of insoluble SOD1
is higher in spinal cords from more severely affected
dogs. This confirms our earlier histopathologic dem-
onstration of cytoplasmic SOD1 aggregate accumula-
tion in the motor neurons from the spinal cords of
DM-affected dogs.4,11 Ogawa et al16 have indepen-
dently shown similarly appearing SOD1 aggregates in
spinal cords from Pembroke Welsh Corgis with DM.
Table 4. Owner reported online survey results for dogs that were sampled when clinically normal and younger















G/G 204 52 25 49 3 6
A/G 177 55 31 53 2 4
A/A 131 30 23 12 18 60
Total 512 137 27 124 23 19
DM, degenerative myelopathy.
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As shown in Table 3, cytoplasmic aggregates contain-
ing SOD1 antigen were found in spinal cord neurons
in all but 1 of the examined dogs with histopathologi-
cally confirmed DM. The exception was a German
Shepherd Dog without any sequence variants in
SOD1 coding regions. Although human SOD1 was
the first gene to be associated with amyotrophic lat-
eral sclerosis (ALS),17 mutations in many additional
genes have been reported to cause ALS.18 It seems
likely that the DM in the German Shepherd Dog
without SOD1 aggregates results from a distinct
genetic or acquired etiology. Among the control dogs,
cytoplasmic aggregates bound anti-SOD1 antibodies
in spinal cord neurons from 6 of 18 SOD1:c.118A
homozygotes and 4 of 25 SOD1:c.118A/G heterozyg-
otes, even though the histopathologic examination of
these cords did not support a diagnosis of DM. Mice
overexpressing mutant human SOD1 transgenes have
been commonly used as models to study ALS. These
murine models develop SOD1-containing aggregates
before their motor neuron deficits become apparent.19
Thus, it seems plausible that some or all of the con-
trol dogs with cytoplasmic SOD1 aggregates were in
a preclinical stage of DM when euthanized. Nonethe-
less, the occurrence of SOD1 aggregates in several of
the control dogs indicates that their presence is not
by itself a reliable diagnostic indicator for DM. In
the previously mentioned transgenic mouse models,
genetic background can affect neurodegeneration
onset or progression.20 This suggests that mean sus-
ceptibility to SOD1-associated DM could differ
among breeds.
All of the dogs with confirmed DM in our earlier
study were SOD1:c.118A homozygotes,3 which sug-
gested an autosomal recessive mode of inheritance.
This differs from the autosomal dominant mode of
inheritance typically seen with human SOD1-associ-
ated ALS.21 We now report that the diagnosis of DM
has been histopathologically confirmed in 8 dogs that
were A/G heterozygotes at SOD1c.118, but had no
other sequence variants predicted to alter the primary
structure of the encoded SOD1. This finding is consis-
tent with the hypothesis that the pathologic mecha-
nisms underlying the development of DM are similar
to the toxic gain-of-function mechanisms believed to
be responsible for the development of SOD1-related
ALS.22 The occurrence of confirmed DM in these 8
SOD1c.118A/G heterozygotes suggested that compared
to SOD1c.118G homozygotes, the heterozygotes are at
increased risk of developing DM. This finding could
call into question the strategy commonly used by dog
breeders who mate SOD1:c.118A homozygotes or
SOD1:c.118A/G heterozygotes only to SOD1:c.118G
homozygotes to avoid the production of new genera-
tions of SOD1:c.118A homozygotes at risk of develop-
ing DM in old age. Thus, we wanted to estimate the
risk of developing DM for dogs with the heterozygous
SOD1c.118A/G genotype relative to SOD1:c.118A
homozygotes and to SOD1:c.118G homozygotes. Most
of our genotype results could not be used for this
purpose because of the strong biases associated with
sample acquisition. Instead, we estimated relative risks
based only on the genotype results for clinically nor-
mal dogs that were sampled at <8 years of age but
that were ≥10 years of age when their clinical status
was recently updated. We considered the results from
these dogs to have a relatively low ascertainment bias
because this cohort of dogs was too young to have
exhibited clinical signs of DM when the samples were
submitted for genotyping. As indicated in Table S5,
we received survey results updating the clinical status
for 137 dogs from 17 breeds. Sixty percent of the 30
SOD1:c.118A homozygous dogs in this cohort devel-
oped clinical signs consistent with DM whereas only
4% of the 55 SOD1:c.118A/G heterozygotes and only
6% of the 53 SOD1:c.118G homozygotes developed
clinical signs of DM (Table 4). This suggests that the
relative risk of developing signs of DM for SOD1:
c.118A/G heterozygotes is similar to that of G/G
homozygotes and much lower than that for SOD1:
c.118A homozygotes. Thus, the above-mentioned
strategy of breeding to avoid the production of
SOD1:c.118A homozygous puppies still appears to be
warranted, particularly in breeds with high SOD1:
c.118A allele frequencies where stricter selection strate-
gies would come at the expense of selecting for other
important traits.
Footnotes
a Whatman FTA Elute cards and swabs; GE Healthcare Life
Sciences, Piscataway, NJ
b Wallac DBS Puncher, PerkinElmer, Waltham, MA
c GoTaq enzyme and buffer; Promega, Madison, WS
d AccuPrimer GC-Rich DNA Polymerase; Invitrogen, Carlsbad,
CA
e QIAquick PCR Purification Kit; Qiagen Inc, Alameda, CA
f Applied Biosystems 3730xl DNA Analyzer, South San
Francisco, CA
g Sequencer 5.0; Gene Codes Corporation, Ann Arbor, MI
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